LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus

K213858 · DiaSorin, Inc. · NXO · Jul 26, 2022 · Immunology

Device Facts

• Record ID: K213858
• Device Name: LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus
• Applicant: DiaSorin, Inc.
• Product Code: NXO · Immunology
• Decision Date: Jul 26, 2022
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5180
• Device Class: Class 2

Indications for Use

The DiaSorin LIAISON® Calprotectin assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the quantitative measurement, in human stool, of fecal calprotectin, a neutrophilic protein that is a marker of mucosal inflammation. The LIAISON® Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn's disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients' clinical evaluation and other diagnostic procedures. The test has to be performed on the LIAISON® Analyzer Family. The DiaSorin LIAISON® Q.S.E.T. Device Plus (Quantitative Stool Extraction and Test) is intended for use in the preparation of human stool specimens for testing in the LIAISON® Calprotectin assay.

Device Story

LIAISON Q.S.E.T. Device Plus is an accessory for the LIAISON Calprotectin assay; used for stool sample collection and extraction. Device consists of a polypropylene tube with 6.0 mL extraction buffer and a grooved sample wand. Replaces manual weighing of stool samples; collects volumetric sample directly from primary specimen container. Used in clinical laboratory settings; operated by laboratory technicians. Extracted samples are loaded onto LIAISON XL or LIAISON XS analyzers. Analyzers perform automated chemiluminescent immunoassay to measure calprotectin concentration. Output is quantitative concentration (μg/g) reported to clinicians. Results aid in diagnosing IBD and differentiating from IBS. Benefits include standardized sample preparation, reduced manual handling, and improved workflow efficiency.

Clinical Evidence

No new clinical diagnostic studies were performed; substantial equivalence is based on analytical performance and method comparison. Method comparison study (n=159) compared Q.S.E.T. Device Plus to the predicate Q.S.E.T. device. Passing-Bablok regression showed a slope of 0.88 (95% CI: 0.84–0.92). Qualitative agreement showed PPA of 97.8% and NPA of 100% (equivocal as negative). Precision studies (n=90 per sample) demonstrated total %CV ranging from 10.5% to 17.6% across the analytical measuring interval.

Technological Characteristics

Sandwich chemiluminescent immunoassay (CLIA). Materials: polypropylene extraction tube, paramagnetic particles, monoclonal antibodies, isoluminol conjugate. Energy source: LIAISON Analyzer (automated). Connectivity: LIAISON Analyzer family. Software: automated calculation of concentration (µg/g). Sterilization: not specified.

Indications for Use

Indicated for patients requiring quantitative measurement of fecal calprotectin to aid in the diagnosis of inflammatory bowel diseases (Crohn's disease and ulcerative colitis) and differentiation from irritable bowel syndrome.

Regulatory Classification

Identification

A fecal calprotectin immunological test system is an in vitro diagnostic device that consists of reagents used to quantitatively measure, by immunochemical techniques, fecal calprotectin in human stool specimens. The device is intended for in vitro diagnostic use as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn's disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome.

Special Controls

The device is classified as Class II under regulation 21 CFR 866.5180 with special controls. The special control guidance document, "Class II Special Controls Guidance Document: Fecal Calprotectin Immunological Test Systems" will be available shortly.

*Classification.* Class II (special controls). The special control for these devices is FDA's guidance document entitled “Class II Special Controls Guidance Document: Fecal Calprotectin Immunological Test Systems.” For the availability of this guidance document, see § 866.1(e).

Predicate Devices

• LIAISON® Calprotectin, LIAISON® Q.S.E.T. Device (K182698)

Submission Summary (Full Text)

{0}

FDA

U.S. FOOD & DRUG

ADMINISTRATION

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

ASSAY ONLY

## I Background Information:

A 510(k) Number

K213858

B Applicant

DiaSorin Inc.

C Proprietary and Established Names

LIAISON Calprotectin

D Regulatory Information

| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| NXO | Class II | 21 CFR 866.5180 - Fecal Calprotectin Immunological Test System | IM - Immunology |

## II Submission/Device Overview:

A Purpose for Submission:

Modification of a cleared device – Addition of the LIAISON Q.S.E.T. Device Plus as stool sample collection and extraction accessory to the cleared LIAISON Calprotectin

B Measurand:

Calprotectin

C Type of Test:

Quantitative, automated immunoassay

## III Intended Use/Indications for Use:

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{1}

K213858 - Page 2 of 9

A Intended Use(s):

See Indications for Use below.

B Indication(s) for Use:

The DiaSorin LIAISON Calprotectin assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the quantitative measurement, in human stool, of fecal calprotectin, a neutrophilic protein that is a marker of mucosal inflammation. The LIAISON Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn's disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients' clinical evaluation and other diagnostic procedures. The test has to be performed on the LIAISON Analyzer Family.

The DiaSorin LIAISON Q.S.E.T. Device Plus (Quantitative Stool Extraction and Test) is intended for use in the preparation of human stool specimens for testing in the LIAISON Calprotectin assay.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

D Special Instrument Requirements:

LIAISON XL Analyzer (K181464)

LIAISON XS Analyzer (K193532)

IV Device/System Characteristics:

A Device Description:

Refer to K182698 for the DiaSorin LIAISON Calprotectin reagent system. Reagent formulations for the LIAISON Calprotectin assay are unchanged.

LIAISON Q.S.E.T Device Plus (optional): The device consists of a polypropylene tube containing 6.0 mL of LIAISON Q.S.E.T. extraction buffer, and a stick shaped with grooves for collecting the sample. The blue upper cap end of the device contains the sample wand, and can be separated from the black inner cap which eliminates excess material from the collection tube containing extraction buffer. Separate instructions are provided for pipetting 12 μL of liquid sample (e.g. Bristol Stool Form Scale [BSFS] type 7) directly into the collection tube of the LIAISON Q.S.E.T. Plus from liquid stool samples. Design, manufacturing, and materials are similar to the Q.S.E.T. extraction device cleared in K182698.

B Principle of Operation:

Refer to K182698 for Test Principle of the LIAISON Calprotectin assay.

{2}

The optional Q.S.E.T. Plus device collects the amount of stool required to perform the LIAISON Calprotectin assay directly from a primary specimen container instead of manually weighing the sample, or using the alternate, cleared Q.S.E.T. device. Following extraction with the Q.S.E.T. Plus device, the sample can be used the LIAISON Calprotectin assay procedure, per K182698.

Pre-analytical processing of fecal samples is accomplished by either manual weight normalization, followed by homogenization in Q.S.E.T. buffer (per K182698); or by using the optional Q.S.E.T (per K182698) or Q.S.E.T. Plus devices for sample collection and homogenization. The Q.S.E.T Device Plus may be loaded directly onto LIAISON XL or LIAISON XS analyzer sample racks.

Following measurement, the assay reports calprotectin concentrations in units of microgram-per-gram of starting fecal sample material $(\mu \mathrm{g} / \mathrm{g})$ . Interpretation of fecal calprotectin concentration [fCal] is as follows:

| [fCal] (μg/g) | Interpretation |
| --- | --- |
| < 50 μg/g | Negative |
| 50 – 120 μg/g | Borderline |
| >120 μg/g | Positive |

# V Substantial Equivalence Information:

# A Predicate Device Name(s):

LIAISON Calprotectin

LIAISON Q.S.E.T. Device

# B Predicate 510(k) Number(s):

K182698

# C Comparison with Predicate(s):

| Device & Predicate Device(s): | K213858 | K182698 |
| --- | --- | --- |
| Device Trade Name(s) | LIAISON Calprotectin LIAISON Q.S.E.T. Device Plus | LIAISON Calprotectin LIAISON Q.S.E.T. Device |
| General Device Characteristic Similarities | | |
| Intended Use/Indications For Use | The DiaSorin LIAISON Calprotectin assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the quantitative measurement, in human stool, of fecal calprotectin, a neutrophilic protein that is a marker of mucosal inflammation. | The DiaSorin LIAISON Calprotectin assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the quantitative measurement, in human stool, of fecal calprotectin, a neutrophilic protein that is a marker of mucosal inflammation. |

K213858 - Page 3 of 9

{3}

K213858 - Page 4 of 9
| | | |
| --- | --- | --- |
| | The LIAISON Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures. The test has to be performed on the LIAISON Analyzer Family.

The DiaSorin LIAISON Q.S.E.T. Device Plus (Quantitative Stool Extraction and Test) is intended for use in the preparation of human stool specimens for testing in the LIAISON Calprotectin assay. | The LIAISON Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures. The test has to be performed on the LIAISON XL Analyzer.

The DiaSorin LIAISON Q.S.E.T. Device (Quantitative Stool Extraction and Test) is intended for use in the preparation of human stool specimens for testing in the LIAISON Calprotectin assay. |
| Specimen Sampling | Unitized specimen probe and sample extraction device | Same |
| Sample normalization | Volumetric | Same |
| Assay processing | Automated | Same |
| Instrumentation | LIAISON XL and XS Analyzers | Same |
| Assay Methodology | Solid-phase (heterogeneous) immunoassay | Same |
| Solid-phase | Paramagnetic microparticles | Same |
| Capture antibodies | Mouse monoclonal anti-human calprotectin | Same |
| Detection antibodies | Mouse monoclonal anti-human calprotectin | Same |
| Detection chemistry | Isoluminol chemiluminescence | Same |
| Assay Output | Quantitative | Same |
| Measurand | Human calprotectin | Same |
| Antigen | Recombinant human calprotectin | Same |
| Interpretation | Normal: <50 µg/g
Borderline: 50 – 120 µg/g
Elevated: >120 µg/g | Same |
| Primary measurement units | Relative Light Units (RLU) | Same |
| Analytical Measuring Range | 5.0 – 800.0 µg/g | Same |

{4}

K213858 - Page 5 of 9

| Extended Analytical Measuring Range | Automated 1:10 dilution: 800.0 – 8000 μg/g | Same |
| --- | --- | --- |
| General Device Characteristic Differences | | |
| Extraction buffer | 6.0 mL pre-loaded extraction buffer | 6.0 mL, separate extraction buffer to be added by user |
| Stool sample specifications | Bristol Stool Form Scale (BSFS) 2–7 | BSFS 2–6 |
| Shelf-Life | 12 months @ 2–8°C
12 months @ 20–24°C | 18 months @ 2–8°C |
| Sample Stability, without centrifugation | 16 weeks @ -20°C
72 hours @ 2–8°C
6 hours @ 20–24°C | 6 hours @ 2–8°C
4 hours @ 20–24°C |
| Sample Stability, with centrifugation | 7 days @ -20°C
1× freeze-thaw cycle | 8 days @ 2–8°C |

## VI Standards/Guidance Documents Referenced:

CLSI EP05-A3, “Evaluation of Precision of Quantitative Measurement Procedures”

## VII Performance Characteristics (if/when applicable):

### A Analytical Performance:

Analytical studies for the Q.S.E.T. Device Plus were performed with the LIAISON Calprotectin assay using the LIAISON XL analyzer.

1. Precision/Reproducibility:

**Q.S.E.T. Device Plus Sample Weight Validation**

The manufacturer performed a study evaluating the precision of the amount of the sample collected by the Q.S.E.T. Device Plus sample collection device. Five stool specimens ranging from Types 2–7 on the Bristol Stool Form Scale (BSFS) were sampled by three operators with five replicates per sample per operator, using three lots of the Q.S.E.T. Device Plus sample collection device. Samples on the Q.S.E.T. Device Plus sample collection device were weighed against the empty weight of the Q.S.E.T. Device Plus device. Results of the study are summarized below:

| Precision of Q.S.E.T. Device Plus Sample Weight | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sample | BSFS | Mean Weight (mg) | Repeatability | | Between-Operator | | Between-Lot | | Within-Lab | |
| | | | SD | %CV | SD | %CV | SD | %CV | SD | %CV |
| 1 | 2 | 10.23 | 1.05 | 10.29 | 0.00 | 0.00 | 0.00 | 0.00 | 1.05 | 10.29 |
| 2 | 4 | 11.02 | 0.87 | 7.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.87 | 7.91 |
| 3 | 5 | 11.79 | 0.73 | 6.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.73 | 6.21 |
| 4 | 6 | 12.00 | 0.67 | 5.56 | 0.00 | 0.00 | 0.25 | 2.04 | 0.71 | 5.93 |
| 5 | 7 | 11.39 | 0.84 | 7.37 | 0.36 | 3.14 | 0.00 | 0.00 | 0.91 | 8.01 |

{5}

The overall precision of sample collection weight was assessed across all five samples, replicates, operators, and lots. The sample weight collected by the Q.S.E.T. Plus is described in the table below:

| Sample collection performance of Q.S.E.T. Device Plus | |
| --- | --- |
| Mean Sample Weight | 11.3 mg |
| Median Sample Weight | 11.4 mg |
| Range | 8.5–13.5 mg |
| 95% CI | 11.2–11.4 mg |
| Standard Deviation | 1.06 mg |
| % Coefficient of Variation | 9.38% |

## Assay Reproducibility

To evaluate the reproducibility of the assay using the Q.S.E.T. Device Plus sample collection device, each of five stool samples representing concentrations spanning the analytical measuring interval (AMI) were extracted daily using the Q.S.E.T. Plus by three operators independently for five days. Extracted samples were tested in one run per day, six replicates per run using one reagent lot by three operators for five days to generate a total of 90 datapoints per sample. The results of this study are summarized below:

| LIAISON fecal calprotectin reproducibility, using the Q.S.E.T. Device Plus | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sample | N | Mean (μg/g) | Repeatability | | Between-Day | | Within-Operator | | Between-Operator | | Total | |
| | | | SD | % CV | SD | % CV | SD | % CV | SD | % CV | SD | % CV |
| 1 | 90 | 17.2 | 0.42 | 2.5 | 1.39 | 8.1 | 1.45 | 8.4 | 1.26 | 7.3 | 1.81 | 10.5 |
| 2 | 90 | 37.9 | 0.88 | 2.3 | 5.63 | 14.9 | 5.69 | 15.0 | 4.29 | 11.3 | 6.67 | 17.6 |
| 3 | 90 | 120 | 2.43 | 2.0 | 12.1 | 10.1 | 12.3 | 10.3 | 6.29 | 5.2 | 12.7 | 10.6 |
| 4 | 90 | 264 | 7.27 | 2.8 | 29.3 | 11.1 | 30.3 | 11.4 | 24.5 | 9.3 | 36.5 | 13.8 |
| 5 | 90 | 1018 | 36.3 | 3.6 | 119 | 11.7 | 124 | 12.1 | 69.4 | 6.8 | 131 | 12.9 |

## 2. Linearity:

Linearity for the LIAISON Calprotectin assay was evaluated in K182698.

## 3. Analytical Specificity/Interference:

Interference for the LIAISON Calprotectin assay was evaluated in K182698.

## 4. Assay Reportable Range:

The assay reportable range for the LIAISON Calprotectin assay was evaluated in K182698.

K213858 - Page 6 of 9

{6}

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Traceability:

Refer to K182698

Reagent Stability:

Refer to K182698 for the reagent kit stability of the LIAISON Calprotectin assay.

Q.S.E.T. Device Plus Stability:

Evaluations of the stability of the Q.S.E.T. Device Plus component, containing buffer were performed on three lots × five timepoints × two temperature conditions, in real-time. The analysis methods, set at an acceptance threshold of ±10% difference from baseline (t₀) were consistent with the recommendations in CLSI EP25-A. Results are summarized below:

| Component | Storage Conditions | Shelf-Life |
| --- | --- | --- |
| Q.S.E.T. Device Plus | 2–8°C | 12 months |
| Q.S.E.T. Device Plus | 20–24°C | 12 months |

Sample Stability:

Critical storage parameters for stool samples were determined for stability, using six samples collected with the Q.S.E.T. Device Plus stored under the conditions in the table below for a minimum of five timepoints, and tested with the LIAISON Calprotectin assay. Acceptable stability duration claims are based on one timepoint prior to the last timepoint with the assay result &lt; ±10% difference from baseline (t₀). Conclusions from these sample stability studies are summarized below:

| Sample Format | Conditions | Stability |
| --- | --- | --- |
| Unextracted sample | -20°C | 16 weeks |
| Unextracted sample | 2–8°C | 72 hours |
| Unextracted sample | 20–24°C | 6 hours |
| Q.S.E.T. Device Plus, containing extracted sample | -20°C | 7 days |
| Q.S.E.T. Device Plus, containing extracted sample | freeze-thaw | 1 freeze-thaw cycle |

6. Detection Limit:

The detection capabilities (i.e. Limit of Blank (LoB), Limit of Detection (LoD), Limit of Quantitation (LoQ)) for the LIAISON Calprotectin assay were evaluated in K182698.

7. Assay Cut-Off:

The assay cut-off for the LIAISON Calprotectin assay was evaluated in K182698.

K213858 - Page 7 of 9

{7}

B Comparison Studies:

1. Method Comparison with Predicate Device:

One-hundred eighty-three (183) human stool samples selected to represent the span of the AMI were extracted with one lot of the Q.S.E.T. Device Plus, as well as one lot of the Q.S.E.T. predicate device. Paired samples from both processing methods were tested in singlicate by the LIAISON Calprotectin assay. Samples outside the valid AMI were excluded for a final $n = 159$. Passing-Bablok regression parameters were calculated and summarized in the following table:

| | Q.S.E.T. Device Plus vs. Q.S.E.T. Device |
| --- | --- |
| n | 159 |
| Range | 5–741 μg/g |
| Slope (95% CI) | 0.88 (0.84–0.92) |
| Intercept (95% CI) | 0.21 (-0.45 – 0.91) |
| Bias @120 μg/g | -14.1 (-15.7 – -9.2) |
| R² | 0.967 |

Qualitative agreement measures derived from the Q.S.E.T. Device Plus were compared to the Q.S.E.T. collection method to evaluate the comparative performance of Q.S.E.T. Device Plus.

| Qualitative performance of Q.S.E.T. Device Plus-extracted samples compared to predicate | | | | | |
| --- | --- | --- | --- | --- | --- |
| | Predicate (Q.S.E.T. Device) | | | | |
| | | (+) | Equivocal | | (-) |
| Q.S.E.T. Device Plus | (+) | 44 | 0 | 0 | 44 |
| | Equivocal | 1 | 14 | 0 | 15 |
| | (-) | 0 | 2 | 98 | 100 |
| | | 45 | 16 | 98 | 159 |
| | | | | | |
| Equivocal considered negative (-) | PPA (95% CI): 97.8% (88.4–99.6%) | | | | |
| | | NPA (95% CI): 100% (96.7–100%) | | | |
| Equivocal considered positive (+) | PPA (95% CI): 96.6% (88.5–99.1%) | | | | |
| | | NPA (95% CI): 100% (96.2–100%) | | | |

2. Matrix Comparison:

Not applicable, as stool is the only sample matrix for this assay.

K213858 - Page 8 of 9

{8}

C Clinical Studies:

Clinical performance for the LIAISON Calprotectin assay was evaluated in K182698.

D Clinical Cut-Off:

Clinical performance for the LIAISON Calprotectin assay was evaluated in K182698.

E Expected Values/Reference Range:

Reference intervals and expected values for the LIAISON Calprotectin assay were evaluated in K182698.

VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

K213858 - Page 9 of 9